Dozens of medicines with the potential to treat pulmonary arterial hypertension (PAH) patients ill with COVID-19 were identified through computer…
Articles by Steve Bryson, PhD
Genes associated with both pulmonary arterial hypertension (PAH) and metabolic syndrome have been identified using computer software tools, a…
Enrollment is now complete in REBUILD, a Phase 3 clinical trial evaluating INOpulse, an investigational treatment for people with…
Two new biomarkers to assess pulmonary arterial hypertension (PAH) were discovered through large-scale analysis of gene activity profiles using…
The identified cause of pulmonary arterial hypertension (PAH) in patients seen at a specialized care center differed substantially from…
Cigarette smoking in men newly diagnosed with pulmonary arterial hypertension (PAH) was associated with a faster time to in-patient…
Children with episodes of fainting due to pulmonary arterial hypertension (PAH) who respond well to a vasodilator given in a…
A blood test for angiopoietin-2 (Ang-2), a protein associated with forming new blood vessels, may predict treatment outcomes in people…
Up to two years of treatment with sotatercept safely maintained gains in heart function and physical abilities in people with…
A protein called LTBP-2 was found to be significantly elevated in people with pulmonary arterial hypertension (PAH), according to…
Extracellular vesicles derived from mesenchymal stem cells eased the signs and symptoms of pulmonary hypertension (PH) in a rat…
Mixed venous oxygen tension (PvO2) — a measure for tissue oxygenation — is a significant predictor of outcomes in…